At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PBM Psyence Biomedical Ltd
Pre-Mkt 03-19 06:05:14 EDT
2.54
-0.05
-1.93%
High2.60Low2.52Vol9.76K
Open2.60D1 Closing2.59Amplitude3.09%
Mkt Cap2.60MTradable Cap2.47MTotal Shares1.02M
T/O24.97KT/O Rate1.01%Tradable Shares970.74K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Psyence Group says GoldCoast raises CAD 5.83 million in financing tied to proposed amalgamation
Reuters  ·  03-18 15:20
Psyence Group says GoldCoast raises CAD 5.83 million in financing tied to proposed amalgamation
Psyence BioMed Plans to Advance Vertically Integrated Platform and Product and Clinical Development Program, Targeting Phase IIb Trial Execution and Regulatory Readiness
Reuters  ·  03-11
Psyence BioMed Plans to Advance Vertically Integrated Platform and Product and Clinical Development Program, Targeting Phase IIb Trial Execution and Regulatory Readiness
Psyence Biomedical appoints Sashank Pillay to board after Seth Feuerstein resigns
Reuters  ·  03-11
Psyence Biomedical appoints Sashank Pillay to board after Seth Feuerstein resigns
Corporate Update: Psyence Biomed Advances Vertically Integrated Pharmaceutical Platform Following Psylabs Export Milestone
THOMSON REUTERS  ·  03-11
Corporate Update: Psyence Biomed Advances Vertically Integrated Pharmaceutical Platform Following Psylabs Export Milestone
BRIEF-Psyence Biomed Announces Export Of Gmp-Manufactured Natural Psilocybin (Npx-5) To Australia For Ongoing Phase Iib Clinical Trial
Reuters  ·  03-03
BRIEF-Psyence Biomed Announces Export Of Gmp-Manufactured Natural Psilocybin (Npx-5) To Australia For Ongoing Phase Iib Clinical Trial
Psyence Biomed Announces Export of Gmp-Manufactured Natural Psilocybin (Npx-5) to Australia for Ongoing Phase Iib Clinical Trial
THOMSON REUTERS  ·  03-03
Psyence Biomed Announces Export of Gmp-Manufactured Natural Psilocybin (Npx-5) to Australia for Ongoing Phase Iib Clinical Trial
Psyence Biomedical Names Sashank Pillay to Board After Seth Feuerstein Resigns
Reuters  ·  03-02
Psyence Biomedical Names Sashank Pillay to Board After Seth Feuerstein Resigns
Psyence extends GoldCoast amalgamation deadline to May 31, 2026
Reuters  ·  02-24
Psyence extends GoldCoast amalgamation deadline to May 31, 2026
Psyence BioMed to Invest $5 Million in PsyLabs via Share-for-Share Exchange
Reuters  ·  02-21
Psyence BioMed to Invest $5 Million in PsyLabs via Share-for-Share Exchange
Psyence Biomed Announces Exercise of Put Option by Psylabs and Strategic Equity Investment
THOMSON REUTERS  ·  02-21
Psyence Biomed Announces Exercise of Put Option by Psylabs and Strategic Equity Investment
Press Release: Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Dow Jones  ·  02-21
Press Release: Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Psyence BioMed Shareholders Approve Up to 250-for-1 Share Consolidation Authority
Reuters  ·  02-19
Psyence BioMed Shareholders Approve Up to 250-for-1 Share Consolidation Authority
Psyence Biomedical announces results of annual, special meeting
TIPRANKS  ·  02-17
Psyence Biomedical announces results of annual, special meeting
Press Release: Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Dow Jones  ·  02-17
Press Release: Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Psyence Biomedical board approves put option agreement with PsyLabs
TIPRANKS  ·  02-14
Psyence Biomedical board approves put option agreement with PsyLabs
Psyence Biomed Approves Put Option Agreement With Psylabs to Secure Strategic Supply and Strengthen Commercialization Pathway
THOMSON REUTERS  ·  02-14
Psyence Biomed Approves Put Option Agreement With Psylabs to Secure Strategic Supply and Strengthen Commercialization Pathway
Psyence BioMed Secures Equity Option for Stake in PsyLabs
Reuters  ·  02-14
Psyence BioMed Secures Equity Option for Stake in PsyLabs
BRIEF-Psyence Biomed Announces Settlement Of Shareholder Litigation
Reuters  ·  02-11
BRIEF-Psyence Biomed Announces Settlement Of Shareholder Litigation
Psyence Biomedical Settles Shareholder Litigation with KAOS Capital for $1.5 Million
Reuters  ·  02-11
Psyence Biomedical Settles Shareholder Litigation with KAOS Capital for $1.5 Million
Psyence Biomedical Ltd - Settlement to Be Funded by Cash on Hand
THOMSON REUTERS  ·  02-11
Psyence Biomedical Ltd - Settlement to Be Funded by Cash on Hand

Introduction

Company Name.
Psyence Biomedical Ltd
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.
Issue price:
--